创新药概念股逆市大涨

Market Overview - The Hong Kong stock market indices closed lower, with the Hang Seng Index down by 0.63%, the Hang Seng Tech Index down by 0.67%, and the Hang Seng China Enterprises Index down by 0.88% [2] - Despite the overall market decline, the innovative drug sector saw significant gains, with the Hang Seng Biotechnology Index rising by 2.97% [2] Company Performance - Technology stocks experienced a broad decline, with Xiaomi Group falling over 3%, closing down by 3.41% [4] - In the innovative drug sector, Huahao Zhongtian Pharmaceutical surged over 55%, while other companies like Kangfang Biotech, Basestone Pharmaceuticals, and Innovent Biologics also saw notable increases of 14.33%, 9.55%, and 6.68% respectively [6][7] Regulatory Developments - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, proposing 16 initiatives across five key areas, including increased R&D support and improved access to insurance [7] IPO Activity - Luxshare Precision announced plans to issue H-shares and list on the Hong Kong Stock Exchange [8] - Lens Technology has initiated its IPO process, aiming to officially list on July 9 [9] - GoerTek plans to spin off its microelectronics subsidiary for an IPO in Hong Kong [10] - These companies are recognized as the "fruit chain three giants," with regulatory support for leading domestic enterprises to list in Hong Kong [11] Market Infrastructure - The Hong Kong Stock Exchange launched an order transmission service for its Integrated Fund Platform, aimed at enhancing market efficiency by connecting key participants in the fund distribution ecosystem [12] - The service is supported by a financial data exchange platform operated by Shenzhen Securities Communication Co., Ltd. [13]